INT918

Context Info Confidence 0.70 First Reported 1975 Last Reported 2010 Negated 3 Speculated 5 Reported most in Abstract Documents 90 Total Number 96 Disease Relevance 23.97 Pain Relevance 40.30

cell proliferation (PRL) cytosol (PRL) extracellular region (PRL)

Anatomy Link Frequency pituitary 8 neurons 6 plasma 4 urine 4 DA neurons 2 PRL (Homo sapiens)

Pain Link Frequency Relevance Heat dopamine receptor 309 100.00 Morphine 181 100.00 opiate 142 100.00 5HT 23 100.00 Dopamine 1545 99.98 Serotonin 765 99.98 fluoxetine 247 99.98 narcan 121 99.98 Opioid 101 99.98 methadone 49 99.98

Disease Link Frequency Relevance Heat Stress 135 100.00 Cancer 105 100.00 Galactorrhea 3020 99.90 Diabetes Mellitus 32 99.80 Gastroesophageal Reflux Disease 23 99.72 Chromophobe Adenoma 1 99.56 Hypoglycemia 12 99.52 Systemic Lupus Erythematosus 51 99.50 Epilepsy 24 99.28 Gastroparesis 23 99.16

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

In order to ascertain whether there is a relation between opioids and the serotoninergic system in prolactin (PRL) secretion increase, we investigated in seven healthy men (21 to 26 years of age) the effect of naloxone, a specific opioid antagonist, on PRL secretion induced by fenfluramine, a drug that stimulates serotonin release and inhibits its re-uptake.

Positive_regulation (increase) of Localization (secretion) of PRL associated with antagonist, narcan, serotonin and opioid

1) Confidence 0.70 Published 1985 Journal Clin. Endocrinol. (Oxf) Section Abstract Doc Link 3987071 Disease Relevance 0 Pain Relevance 0.44

Naloxone reduces the fenfluramine-induced prolactin release in man.

Positive_regulation (induced) of Localization (release) of prolactin associated with narcan

2) Confidence 0.70 Published 1985 Journal Clin. Endocrinol. (Oxf) Section Title Doc Link 3987071 Disease Relevance 0 Pain Relevance 0.72

Higher doses of naloxone (30 mg) do not further inhibit the PRL secretion induced by fenfluramine.

Positive_regulation (induced) of Localization (secretion) of PRL associated with narcan

3) Confidence 0.70 Published 1985 Journal Clin. Endocrinol. (Oxf) Section Abstract Doc Link 3987071 Disease Relevance 0 Pain Relevance 0.72

They observed that naloxone is not able to reduce either basal PRL secretion in menopausal women, or puerperal hyperprolactinemia, or PRL release induced by mechanical breast stimulation.

Positive_regulation (induced) of Localization (release) of PRL associated with galactorrhea, endometriosis (extended) and narcan

4) Confidence 0.70 Published 1983 Journal Acta Eur. Fertil. Section Abstract Doc Link 6326452 Disease Relevance 0.37 Pain Relevance 0.50

In normal humans, ingestion of protein stimulates PRL secretion.

Positive_regulation (stimulates) of Localization (secretion) of PRL

5) Confidence 0.70 Published 1989 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 2732299 Disease Relevance 0 Pain Relevance 0.03

Administration of naloxone, phentolamine, or propranolol did not alter the PRL response to the various test meals, indicating that neither opioid, alpha-adrenergic, nor beta-adrenergic stimulation is involved in meal-induced PRL secretion.

Neg (neither) Positive_regulation (induced) of Localization (secretion) of PRL associated with narcan and opioid

6) Confidence 0.70 Published 1989 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 2732299 Disease Relevance 0 Pain Relevance 0.19

Enhancement of insulin-induced prolactin secretion by fluoxetine in man.

Positive_regulation (Enhancement) of Localization (secretion) of prolactin associated with fluoxetine

7) Confidence 0.70 Published 1979 Journal J. Clin. Endocrinol. Metab. Section Title Doc Link 313936 Disease Relevance 0 Pain Relevance 0.43

Fluoxetine significantly enhanced insulin-induced PRL release.

Positive_regulation (enhanced) of Localization (release) of PRL associated with fluoxetine

8) Confidence 0.70 Published 1979 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 313936 Disease Relevance 0 Pain Relevance 0.40

Morphine inhibits cortisol and stimulates prolactin secretion in man.

Positive_regulation (stimulates) of Localization (secretion) of prolactin associated with morphine

9) Confidence 0.70 Published 1984 Journal Psychoneuroendocrinology Section Title Doc Link 6514937 Disease Relevance 0 Pain Relevance 0.73

Morphine stimulated prolactin release.

Positive_regulation (stimulated) of Localization (release) of prolactin associated with morphine

10) Confidence 0.70 Published 1984 Journal Psychoneuroendocrinology Section Abstract Doc Link 6514937 Disease Relevance 0 Pain Relevance 0.75

Monotherapy-treated patients rarely reported symptoms due to increased prolactin secretion, while in patients on antipsychotic drugs that stimulate prolactin secretion, serotoninergic antidepressants may elevate prolactin levels above symptomatic levels or worsen pre-existing symptoms (Haddad and Wieck 2000).

Positive_regulation (stimulate) of Localization (secretion) of prolactin associated with antidepressant

11) Confidence 0.70 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376090 Disease Relevance 0.20 Pain Relevance 0.53

Monotherapy-treated patients rarely reported symptoms due to increased prolactin secretion, while in patients on antipsychotic drugs that stimulate prolactin secretion, serotoninergic antidepressants may elevate prolactin levels above symptomatic levels or worsen pre-existing symptoms (Haddad and Wieck 2000).

Positive_regulation (increased) of Localization (secretion) of prolactin associated with antidepressant

12) Confidence 0.70 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376090 Disease Relevance 0.16 Pain Relevance 0.50

Fluoxetine induces a 5HT receptor–mediated stimulation of prolactin secretion and is reported to increase prolactin levels more than tricyclics (Meltzer et al 1997).

Positive_regulation (induces) of Localization (secretion) of prolactin associated with 5ht and fluoxetine

13) Confidence 0.70 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376090 Disease Relevance 0.91 Pain Relevance 0.99

SSRI actually cause little, if any, increase in prolactin secretion.

Neg (little) Positive_regulation (increase) of Localization (secretion) of prolactin associated with ssri

14) Confidence 0.70 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376090 Disease Relevance 0.37 Pain Relevance 0.73

Since it is prevented by a previous injection of the specific opiate antagonist naloxone, morphine- and methadone-induced prolactin secretion seems to be primarily mediated by ?

Positive_regulation (mediated) of Localization (secretion) of prolactin associated with antagonist, narcan, methadone, opiate and morphine

15) Confidence 0.70 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376090 Disease Relevance 0.05 Pain Relevance 1.16

Opioids may indirectly stimulate prolactin release by inhibiting PIFs (ie, dopamine) release and/or by stimulating PRFs production (Shin et al 1988) (Figure 2).

Spec (may) Positive_regulation (stimulate) of Localization (release) of prolactin associated with dopamine and opioid

16) Confidence 0.70 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376090 Disease Relevance 0.17 Pain Relevance 0.99

Since it is prevented by a previous injection of the specific opiate antagonist naloxone, morphine- and methadone-induced prolactin secretion seems to be primarily mediated by ?

Positive_regulation (induced) of Localization (secretion) of prolactin associated with antagonist, narcan, methadone, opiate and morphine

17) Confidence 0.70 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376090 Disease Relevance 0.05 Pain Relevance 1.13

L-sulpiride is an antagonist of dopamine on D2 receptors therefore inhibits the action of dopamine increasing the secretion of prolactin.

Positive_regulation (increasing) of Localization (secretion) of prolactin associated with dopamine and antagonist

18) Confidence 0.70 Published 1989 Journal Minerva Anestesiol Section Abstract Doc Link 2601863 Disease Relevance 0.50 Pain Relevance 0.27

Droperidol-induced increase in prolactin secretion was significant already at ten minutes after the administration reaching the peak after 20 minutes.

Positive_regulation (increase) of Localization (secretion) of prolactin

19) Confidence 0.70 Published 1989 Journal Minerva Anestesiol Section Abstract Doc Link 2601863 Disease Relevance 0.42 Pain Relevance 0.23

L-sulpiride increased prolactin secretion reaching the maximum increase 20 minutes after the administration of 50 mg of the drug, and 30 minutes after the administration of 100 mg doses.

Positive_regulation (increased) of Localization (secretion) of prolactin

20) Confidence 0.70 Published 1989 Journal Minerva Anestesiol Section Abstract Doc Link 2601863 Disease Relevance 0.39 Pain Relevance 0.21

General Comments

This test has worked.